Working... Menu

Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03241472
Recruitment Status : Completed
First Posted : August 7, 2017
Last Update Posted : August 7, 2017
Information provided by (Responsible Party):
Ahmed Mohamed Abbas, Assiut University

Brief Summary:
Infertility is defined as a couple's inability to become pregnant after one year of unprotected intercourse in women 35 years old and younger, and for six months in women over age 35 years. In any given year, about 15 percent of couples in North America and Europe who are trying to conceive are infertile

Condition or disease Intervention/treatment Phase
Infertility Drug: Letrozole Drug: Clomiphene Citrate plus N acetyl cystine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole
Actual Study Start Date : February 2016
Actual Primary Completion Date : May 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: Lertozole
oral tablets 5 mg start from third day cycle for 5 days
Drug: Letrozole
oral tablets 5 mg

Active Comparator: clomiphene plus N- acetyl cystiene
clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
Drug: Clomiphene Citrate plus N acetyl cystine
Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg

Primary Outcome Measures :
  1. rate of ovulation [ Time Frame: 3 months ]
    ultrasound evaluation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All primary and secondary. Infertility due to anovulation

Exclusion Criteria:

  • Male factor infertility, tubal factor.
  • Endocrineopathy
  • Hypothyrodism
  • Morbid obesity
  • Under weight
  • Patient with previous surgery including drilling of ovary, Clomiphene Citrate resistant to ovulation.

Layout table for additonal information
Responsible Party: Ahmed Mohamed Abbas, principal investigator, Assiut University Identifier: NCT03241472     History of Changes
Other Study ID Numbers: NACLET
First Posted: August 7, 2017    Key Record Dates
Last Update Posted: August 7, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Diseases, Male
Genital Diseases, Female
Citric Acid
Sodium Citrate
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Antiviral Agents